Abpro Holdings, Inc.

Equities

ABPO

US0008472021

Biotechnology & Medical Research

End-of-day quote OTC Markets Other stock markets 17/04/2026			5-day change	1st Jan Change
0.1442 ^USD	-3.87%		+38.65%	-96.59%

04-15	Abpro Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
02-25	Abpro Holdings, Inc.(NasdaqCM:ABP) dropped from S&P TMI Index	CI

Abpro Holdings, Inc. Announces Termination of Robert J. Markelewicz as Chief Medical Officer, Effective November 30, 2025

Published on 10/02/2025 at 09:15 pm BST

S&P Capital IQ

ABPRO HOLDINGS, INC.

-3.87%

On September 30, 2025, Abpro Holdings, Inc. furloughed Robert J. Markelewicz, Jr., M.D., M.M.Sc., the Company?s Chief Medical Officer, effective September 30, 2025 until November 30, 2025. During the furlough period, Dr. Markelewicz will not perform any duties or responsibilities associated with his role. Dr. Markelewicz?s employment will be terminated effective November 30, 2025.

Latest news about Abpro Holdings, Inc.

04-15	Abpro Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
02-25	Abpro Holdings, Inc.(NasdaqCM:ABP) dropped from S&P TMI Index	CI
02-19	Abpro Holdings, Inc.(OTCPK:ABPO) dropped from NASDAQ Composite Index	CI
02-03	Abpro Holdings, Inc. Announces Board and Committee Resignations	CI
01-23	Abpro Holdings, Inc. Announces Board and Committee Changes	CI
01-16	Abpro Holdings, Inc. announced that it expects to receive $0.147 million in funding	CI
01-06	Abpro, Celltrion Say Solid Cancer Tumor Therapy Investigational New Drug Application Receives US FDA Clearance	MT
01-06	Abpro Holdings, Inc. and Celltrion, Inc. Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72	CI
12-15	Abpro Holdings announces submission of an IND application to initiate a Phase 1 clinical trial of T cell engager ABP-102/CT-P72 for HER2-positive cancers	RE
12-15	Abpro Holdings, Inc. and Celltrion, Inc. Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T Cell Engager ABP-102/CT-P72 for HER2-Positive Cancers	CI
11-14	Abpro Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-07	Abpro Holdings files prospectus related to the offer and resale of up to 9.78 million shares of common stock - SEC filing	RE
22/10/25	Abpro Holdings Inc - to effect one-for-thirty reverse stock split - SEC filing	RE
02/10/25	Abpro Holdings, Inc. Announces Termination of Robert J. Markelewicz as Chief Medical Officer, Effective November 30, 2025	CI
13/08/25	Abpro Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI

Chart Abpro Holdings, Inc.

Duration

Period

ABPO: Dynamic Chart

Company Profile

Abpro Holdings, Inc. is a biotechnology company dedicated to developing next-generation antibody therapeutics, which helps in improving the lives of patients with severe and life-threatening diseases. The Company is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its DiversImmune and MultiMab antibody discovery and engineering platforms, it is engaged in developing a pipeline of antibodies, both independently and through collaborations with global pharmaceutical and research institutions. Its two lead product candidates, ABP-102 and ABP-201, feature its next generation tetravalent antibody format (TetraBi antibody format), which binds to two different targets with two distinct binding sites per target. ABP-102 is designed to redirect a patientâ€™s immune system to fight cancer by engaging T cells through co-targeting human epidermal growth factor receptor 2 (HER2), and cluster of differentiation 3 (CD3), T-cell co-receptor.

Employees

Sector

Biotechnology & Medical Research

More about the company

Income Statement and Estimates

More financial data

Quarterly revenue - Rate of surprise

Company calendar